Tumor Pathology
Traditional pathology provides only limited spatially-resolved molecular information. Molecular Cartography™ generates detailed molecular landscapes of complex tissues for improved pathological classification.
-
Comprehensive molecular characterization of the tumor microenvironment and dissection of cell type composition
-
Enhanced precision in disease diagnosis and patient stratification
-
Power (pre-)clinical studies with high-resolution spatial analysis
Paving the Way to Precision Medicine
Our Applications
What if we could map the tumor microenvironment in exceptional detail?
The Challenge
Tumors evolve within complex tissue environments shaped by diverse spatial components, specialized niches, and dynamic cell-cell interactions. These factors play a critical role in tumor progression, treatment response, and ultimately, patient outcomes.
The Solution
Molecular Cartography™ precisely maps complex tumor ecosystems at subcellular resolution, providing deep insights into spatial interactions and molecular profiles. Empower your research to transform spatial complexity into targeted clinical strategies.
Molecular Cartography™ RNA assay visualizations of diverse FFPE tissue samples with the same 100-plex immuno-oncology (I/O) gene panel. Highlighted are detected transcripts of six genes that are specific for major cell populations.
Immuno-Oncology
The interplay between tumor cells and the immune system is highly dynamic and complex. Molecular Cartography™ enables fine-grained classification of immune cell types and states as well as their interactions within the tumor microenvironment.
-
Distinguish between pro- and anti-tumorigenic immune cell states
-
Resolve functional interactions based on ligand-receptor co-localization
-
Identify biomarkers and mechanisms of immunotherapy treatment response
Spatial localization of cell types in a variety of tumor FFPE samples and associated UMAP embedding of gene expression using our immuno-oncology (I/O) gene panel. The animation shows the robustness of our platform in detecting key cell types in different tumor specimens, independent of the tumor type.
Therapeutics Development
Despite recent progress, tumor therapy response rates are still low. Molecular Cartography™ can support key steps in drug development, from discovery and optimization to validation in clinical studies.
-
Identify spatial biomarkers that correlate with treatment responses
-
Unveil mechanisms of therapy resistance
-
Identify new cancer vulnerabilities and therapeutic targets
Regulatory CD4+ T-cells (Tregs) in contact with CD274+ (PD-L1) breast tumor cells show high expression of SELL (CD62L), which indicates the presence of immuno-suppressive capacity in specific regions of the FFPE tumor specimen and has implications for treatment decisions and strategies involving PD1/PD-L1 inhibitors.